A new adrenaline autoinjector is now available on the Pharmaceutical Benefits Scheme (PBS). Anapen® offers another option to the Epipen® for patients who are at risk of anaphylaxis.

Anapen® and Epipen® are both available in 150mcg and 300mcg strengths. The 150mcg autoinjector is marketed as the ‘junior’ presentation and may be considered for children weighing between 15 and 30kg. The 300mcg strength is recommended for patients weighing 30kg and over. Anapen® is also available in a 500mcg presentation which may be considered for adults over 60kg, depending on clinical judgement. For PBS purposes, the 150mcg and 300mcg presentations of Anapen® are substitutable with the corresponding strength of Epipen®.

Both brands of adrenaline autoinjectors are administered intramuscularly into the anterolateral aspect of the thigh. It is important that patients familiarise themselves with the administration instructions specific to their device before the device is required. Information on how to give Anapen® and Epipen® are available on the Australasian Society of Clinical Immunology and Allergy (ASCIA) website.


  1. Anapen® (Adrenaline (epinephrine)) Australian approved product information. Sydney: Allergy Concepts. Approved March 2021.
  2. Epipen® (Adrenaline (epinephrine)) Australian approved product information. Millers Point: Alphapharm. Approved July 2021.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates